DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ACALABRUTINIB

« Back to Dashboard

Clinical Trials for Acalabrutinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02029443	ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1/Phase 2	2014-01-01	This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
NCT02157324	Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-08-01	This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
NCT02180711	An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma	Active, not recruiting	Acerta Pharma, LLC	Phase 1	2014-07-01	To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02180711	An Open-label, Phase 1b Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma	Active, not recruiting	Acerta Pharma BV	Phase 1	2014-07-01	To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with relapsed,refractory,or treatment naive Follicular Lymphoma (FL)
NCT02211014	An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma	Active, not recruiting	Acerta Pharma, LLC	Phase 1	2015-02-01	To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
NCT02211014	An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma	Active, not recruiting	Acerta Pharma BV	Phase 1	2015-02-01	To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)

Clinical Trial Conditions for Acalabrutinib

Condition Name

Condition Name for Acalabrutinib
Intervention	Trials
Chronic Lymphocytic Leukemia	13
Small Lymphocytic Lymphoma	4
Mantle Cell Lymphoma	3
DLBCL	3

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Acalabrutinib
Intervention	Trials
Leukemia, Lymphoid	16
Leukemia, Lymphocytic, Chronic, B-Cell	16
Lymphoma	15
Leukemia	13

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Acalabrutinib

Trials by Country

Trials by Country for Acalabrutinib
Location	Trials
United States	87
United Kingdom	7
Canada	4
Italy	3
Spain	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Acalabrutinib
Location	Trials
Ohio	10
Washington	7
Texas	7
New York	7
Maryland	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Acalabrutinib

Clinical Trial Phase

Clinical Trial Phase for Acalabrutinib
Clinical Trial Phase	Trials
Phase 3	7
Phase 2/Phase 3	1
Phase 2	16

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Acalabrutinib
Clinical Trial Phase	Trials
Not yet recruiting	16
Recruiting	12
Active, not recruiting	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Acalabrutinib

Sponsor Name

Sponsor Name for Acalabrutinib
Sponsor	Trials
Acerta Pharma BV	25
AstraZeneca	6
Merck Sharp & Dohme Corp.	4

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Acalabrutinib
Sponsor	Trials
Industry	37
Other	19
NIH	5

Export unavailable in trial.
Subscribe for complete access.